Diagnostic technology goes 3D
New research study demonstrates applicability of VisionGate’s Cell-CT platform
SEATTLE—New research conducted by Arizona State University’s (ASU) Biodesign Institute and published in Science Advances (a publication of the American Association for the Advancement of Science) has reportedly revealed for the first time the application of three-dimensional optical computed tomography (3D optical CT) on the cellular imaging of live cells.
According to VisionGate, this study further demonstrates that the 3D optical CT approach used by VisionGate’s Cell-CT Imaging and Analysis Platform provides a significant advantage over other 3D imaging modalities that are based on conventional 2D microscopy. The company also touts that “the emergence of live-cell CT adds the fourth dimension of time.”
The study’s principal investigator, Prof. Deirdre Meldrum, commented that “the Cell-CT platform combined with live-cell imaging and fluorescence marker analysis will revolutionize our understanding of disease at the cellular level, where disease prediction and companion diagnostics for personalized medicine are poised to change the paradigm for improved healthcare.”
Moreover, VisionGate maintains that these study findings validate that the principles of the Cell-CT technology can be expanded into the realm of live-cell imaging and analysis. The technology was originally developed by VisionGate, and the company is nearing commercialization of the Cell-CT platform for the detection of early-stage lung cancer.
VisionGate also says that its “evolving capability to perform true three-dimensional imaging at the single-cell level holds the promise to enable better understanding of how cells function, opening the door for development of new diagnostic methods and ultimately the development of new medicines.”